Loading...
OTCM
EKTAF
Market cap2.07bUSD
Oct 07, Last price  
5.36
Name

Elekta AB (publ)

Chart & performance

D1W1MN
OTCM:EKTAF chart
P/E
—
P/S
—
EPS
—
Vol. 1Y
—
Shs. 5Y
0.08%
Rev. 5Y
3.97%
Div Yld LY
—
Div Yld TTM
—
Revenues
16.72b
-7.20%
4,525,000,0005,081,000,0006,689,000,0007,392,000,0007,904,000,0009,048,000,00010,339,000,00010,694,000,00010,839,000,00011,221,000,00010,704,000,00011,333,000,00013,555,000,00014,601,000,00013,763,000,00014,548,000,00016,869,000,00018,119,000,00018,016,000,00016,718,000,000
Net income
-520m
L
348,000,000406,000,000546,000,000833,000,0001,031,000,0001,227,000,0001,340,000,0001,148,000,000552,000,000137,000,000125,000,0001,099,000,0001,198,000,0001,084,000,0001,254,000,0001,154,000,000943,000,0001,302,000,000237,000,000-520,000,000
CFO
2.46b
-6.17%
150,000,000319,000,000740,000,0001,056,000,000840,000,000635,000,0001,870,000,0001,275,000,0001,823,000,0001,170,000,0001,819,000,0002,404,000,0001,621,000,0001,014,000,0002,551,000,0001,858,000,0001,964,000,0002,461,000,0002,626,000,0002,464,000,000
Dividend
Mar 04, 20270.12048 /sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Elekta AB (publ) is a global medical technology company dedicated to developing and delivering advanced clinical solutions for the treatment of cancer and brain disorders. Its comprehensive portfolio includes innovative radiotherapy systems such as the Elekta Unity MR-Linac, the Elekta Harmony linear accelerator, Elekta Infinity for diverse patient radiotherapy requirements, and the Elekta Synergy digital accelerator for advanced image-guided radiation therapy. Specific solutions like Versa HD are available for managing brain metastases. The company also supplies crucial treatment management software, automated and integrated quality assurance tools, and hardware and software for motion management. Further augmenting its oncology offerings, Elekta provides MOSAIQ Plaza for integrated multidisciplinary cancer care and Elekta Axis Cloud for managed hosting. Within brachytherapy, key products include the image-guided Elekta Studio, the mobile ImagingRing CT scanner, Oncentra Brachy for streamlining repetitive tasks, the Elekta Flexitron afterloader for precise workflow execution, and specialized applicators like Venezia and Geneva for cervical cancer treatment. For neurological conditions, Elekta offers a suite of advanced radiosurgery and neurosurgery solutions. This includes the Leksell Gamma Knife series – Icon for personalized radiation treatment, Perfexion for neurosurgical applications, and Lightning for accelerated procedures. Its neurosurgery product line features the Leksell Vantage Stereotactic System for intracranial interventions and the Leksell Stereotactic System for minimally invasive stereotactic neurosurgery. Founded in 1972, Elekta maintains its corporate headquarters in Stockholm, Sweden.

Related entities

Subsidiaries (2)
Elekta Instrument AB
Elekta Solutions AB

Key people

Laurent Leksell
Chairman of the Board · since 2022
Klara Eiritz
Chief Financial Officer, Member of the Executive Committee · since 2026
Anna Lundgren
Executive Vice President, Chief People Officer, Member of the Executive Committee · since 2023
Jonas Bolander
Executive Vice President - Group Functions, General Counsel, Member of the Executive Committee · since 2025
Christopher Busch
President - Linac & Software Solutions, Member of the Executive Committee · since 2024
John Lapre
President - Brachy & Neuro Solutions, Member of the Executive Committee · since 2023
Habib Nehme
Chief Commercial Officer, Member of the Executive Committee · since 2023
Independent Director · since 2024
Independent Director · since 2023
Jan Kimpen
Independent Director · since 2024
Wolfgang Reim
Independent Director · since 2011
Jan Secher
Independent Director · since 2010
Volker Wetekam
Independent Director · since 2023
Cecilia Wikstroem
Independent Director · since 2018
IPO date
Mar 01, 1994
Employees
4,700
Domiciled in
SE
Incorporated in
SE
Headquarters & legal address
Box 7593
Stockholm, AB 103 93
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑042025‑042024‑042023‑042022‑042021‑042020‑042019‑042018‑042017‑04
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT